IRX3 and lymphoid leukemia: IRX3 was highly expressed in approximately 30% of patients with AML, and high expression of IRX3 alone can perpetuate hematopoietic stem cells and progenitor cells (HSPC) in bone marrow cultures and induce lymphoid leukemia in vivo (Somerville et al., 2018).